
                                SEQUENCE LISTING

<110> California Institute of Technology

<120> CYCLIC PEPTIDES AS PROTEIN TARGETING
  AGENTS

<130> 481274.401WO

<140> PCT                 
<141> 2014-06-20  

<150> US 61/925,058       
<151> 2014-01-08  

<150> US 61/837,556       
<151> 2013-06-20  

<160> 39

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 1
Tyr Val Tyr Lys Ser
 1               5

<210> 2
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 2
Val Phe Ala Lys Val
 1               5

<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 3
Ile Arg Tyr Tyr Ser
 1               5

<210> 4
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 4
Tyr Tyr Thr Tyr Thr
 1               5

<210> 5
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 5
Arg Gly Gly Ile Leu
 1               5

<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 6
Lys Lys Ile His Leu
 1               5

<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 7
Ile Leu Tyr Trp Lys
 1               5

<210> 8
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 8
Pro Leu Lys Lys Gly
 1               5

<210> 9
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 9
Leu Lys Thr Gly Gln
 1               5

<210> 10
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 10
Leu Lys Thr Gly Thr
 1               5

<210> 11
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 11
His Trp Ser Ala Asn
 1               5

<210> 12
<211> 4
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 12
Tyr Trp Gln Trp
 1

<210> 13
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 13
Gly His Trp Ser Ala Asn
 1               5

<210> 14
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 14
Tyr Leu Gly His Lys
 1               5

<210> 15
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 15
Leu Ala Tyr Pro Pro
 1               5

<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 16
Leu Ala Tyr Pro Ala
 1               5

<210> 17
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 17
Leu Ala Tyr Ala Ala
 1               5

<210> 18
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 18
Leu Ala Tyr Ala Pro
 1               5

<210> 19
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 19
Glu Leu Tyr Lys Tyr
 1               5

<210> 20
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 20
Gly Ile Phe Ala Val Thr
 1               5

<210> 21
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 21
Gly Ile Val Gly Ala Pro
 1               5

<210> 22
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 22
Gly Asn Trp Pro Ala Ala
 1               5

<210> 23
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 23
Gly Phe Asn Val Asp Leu
 1               5

<210> 24
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 24
Gly Trp Asn Val Asp Leu
 1               5

<210> 25
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 25
Gly Ser Thr Glu Trp Leu
 1               5

<210> 26
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 26
Gly Ser Gln Glu Trp Leu
 1               5

<210> 27
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 27
Gly Thr Glu Ser Val Ala
 1               5

<210> 28
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 28
Gly Gln Ile Thr Ile Tyr
 1               5

<210> 29
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 29
Gly Gln Ile Gln Ile Tyr
 1               5

<210> 30
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 30
Gly Thr Ile Thr Ile Tyr
 1               5

<210> 31
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 31
Gly Thr Ile Gln Ile Tyr
 1               5

<210> 32
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 32
Gly Thr Ala Val Asn Ala
 1               5

<210> 33
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide selected to have an affinity for
      desired target, including allosteric binding sites
      such as peptide epitopes.

<400> 33
Gly Gln Ala Val Asn Ala
 1               5

<210> 34
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> Peptide epitope specific for the plasmodium
      falciparum LDH protein.

<400> 34
Leu Ile Ser Asp Ala Glu Leu Glu Ala Ile Phe Asp
 1               5                  10

<210> 35
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> Peptide epitope specific for the plasmodium
      falciparum LDH protein.

<400> 35
Asp Asp Ile Ala Ile Leu Glu Glu Phe Ala Leu Ser
 1               5                  10

<210> 36
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> Peptide epitope specific for the malarial parasite
      LDH protein.

<400> 36
Gly Val Glu Gln Val Ile Glu Leu Gln Leu Asn
 1               5                  10

<210> 37
<211> 26
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic N-terminal sequence
      

<400> 37
Met Val Ser Phe Ser Lys Asn Lys Val Leu Ser Ala Ala Val Phe Ala
 1               5                  10                  15
Ser Val Leu Leu Leu Asp Asn Asn Asn Ser
            20                  25

<210> 38
<211> 29
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic N-terminal sequence
      

<400> 38
Phe Asn Asn Asn Leu Cys Ser Lys Asn Ala Lys Gly Leu Asn Leu Asn
 1               5                  10                  15
Lys Arg Leu Leu His Glu Thr Gln Ala His Val Asp Asp
            20                  25

<210> 39
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic C-terminal sequence
      

<400> 39
Ala His His Ala Thr Asp Ala His His Ala Ala Ala His His Glu Ala
 1               5                  10                  15
Ala Thr His Cys
            20
